Iradimed Co (IRMD)

Iradimed Co is a healthcare equipment company focused on products designed for use in magnetic resonance imaging (MRI) environments. Through its operating business, IRADIMED Corporation develops, manufactures, markets, and distributes MRI-compatible intravenous infusion pump systems, patient vital signs monitoring systems, and related accessories. Its product set includes the MRidium 3870 and 3860+ infusion pump systems, the 3880 MRI-compatible patient monitoring system, and the 3600 FMD1 ferromagnetic detection device with remote alarm logging functionality. The company also supplies non-magnetic IV poles, wireless remote displays and controls, side car pump modules, dose error reduction systems, and SpO2 monitoring components. IRADIMED serves hospitals, acute care facilities, and outpatient imaging centers, with sales supported by direct field representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and international markets. Incorporated in 1992, the company is headquartered in Orlando, Florida.


Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-IRMD
$64.58
-25.4% Downside
Overvalued
$118
36.4% Upside
Undervalued
Great
1.0%
October 29, 2026
48.0x
10.9x
12.8x
1.106 B
1.047 B
0.0%
65.2%
51.1
68.7%
108.9%
Valuation • Fair Value

Iradimed Co (NASDAQ-IRMD) Fair Value by Valuation Model

Review the available estimates for Iradimed Co (NASDAQ-IRMD), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$64.58

Estimated downside of 25.4% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$63.85

Discounted cash flow valuation reference.

Ben Graham Formula Value

$20.01

Classic Ben Graham valuation formula reference.

DDM Fair Value

$58.04

Dividend discount model valuation reference.

Comps Fair Value

$67.48

Comparable-company valuation reference.

Analyst Price Target

$118

Analysts imply upside of 36.4%.

How to read these valuation models

Use the 7 available valuation references for Iradimed Co (NASDAQ-IRMD) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Iradimed Co (NASDAQ-IRMD)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

86.338 M

Current operating scale indicator.

Revenue Forecast

91.2 M

Forward revenue estimate.

EBITDA

29.184 M

Current operating profitability reference.

EBITDA Forecast

31.7 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Iradimed Co (NASDAQ-IRMD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Iradimed Co (NASDAQ-IRMD)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Beneish M-Score

-2.65

No elevated caution signal from this screen.

Altman Z-Score

51.1

Relatively strong balance-sheet zone.

FCF / Net Income

108.9%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Iradimed Co (NASDAQ-IRMD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Iradimed Co (NASDAQ-IRMD)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 29, 2026

Days to Earnings

37

Dividend Yield

1.0%

Current income yield reference.

Payout Ratio

68.7%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Iradimed Co (NASDAQ-IRMD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Iradimed Co (NASDAQ-IRMD) Stock Forecast & Technical Outlook

Review Iradimed Co (NASDAQ-IRMD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Iradimed Co (NASDAQ-IRMD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Iradimed Co (NASDAQ-IRMD) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Iradimed Co (NASDAQ-IRMD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Iradimed Co (NASDAQ-IRMD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Buy

The monthly technical read for Iradimed Co (NASDAQ-IRMD) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Iradimed Co (NASDAQ-IRMD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Iradimed Co (NASDAQ-IRMD) has a Buy consensus, with 2 buy, 1 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 1
Sell 0
FAQ Fast Investor Answers

Iradimed Co (NASDAQ-IRMD) Stock FAQ

Data-supported answers about Iradimed Co (NASDAQ-IRMD), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$64.58
Estimated downside 25.4%
Valuation Rating
Overvalued
Estimated downside of 25.4%
Analyst Target
$118
Implied upside 36.4%
Financial Health
Great
Current financial-health read

The current fair value estimate for Iradimed Co (NASDAQ-IRMD) is $64.58. This implies an estimated downside of 25.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 25.4% versus the current market price.

The available analyst price target for Iradimed Co (NASDAQ-IRMD) is $118. The analyst target implies estimated upside of 36.4%.

The current financial health read for Iradimed Co (NASDAQ-IRMD) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Iradimed Co (NASDAQ-IRMD) is October 29, 2026.

Based on the current data, dividend yield is 1.0%.

The current P/E ratio listed for Iradimed Co (NASDAQ-IRMD) is 48.0x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Iradimed Co is 1.106 B.

The current enterprise value listed for Iradimed Co is 1.047 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Iradimed Co is NASDAQ-IRMD, and the stock is listed on NASDAQ.

Iradimed Co (NASDAQ-IRMD) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Iradimed Co is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Iradimed Co is 65.2%. Free float helps investors understand how much of the share base is available for public trading.